Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 343

1.

Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial.

Gibb DM, Goodall RL, Giacomet V, McGee L, Compagnucci A, Lyall H; Paediatric European Network for Treatment of AIDS Steering Committee..

Pediatr Infect Dis J. 2003 Jan;22(1):56-62.

PMID:
12544410
2.

Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children.

van Rossum AM, Bergshoeff AS, Fraaij PL, Hugen PW, Hartwig NG, Geelen SP, Wolfs TF, Weemaes CM, De Groot R, Burger DM.

Pediatr Infect Dis J. 2002 Aug;21(8):743-7.

PMID:
12192162
3.

Adherence to medication regimens among children with human immunodeficiency virus infection.

Reddington C, Cohen J, Baldillo A, Toye M, Smith D, Kneut C, Demaria A, Bertolli J, Hsu HW.

Pediatr Infect Dis J. 2000 Dec;19(12):1148-53.

PMID:
11144374
4.

Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection.

Van Dyke RB, Lee S, Johnson GM, Wiznia A, Mohan K, Stanley K, Morse EV, Krogstad PA, Nachman S; Pediatric AIDS Clinical Trials Group Adherence Subcommittee Pediatric AIDS Clinical Trials Group 377 Study Team..

Pediatrics. 2002 Apr;109(4):e61.

PMID:
11927734
5.

Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection.

Hoffmann F, Funk M, Linde R, Notheis G, Petropoulou T, Eberle J, Gürtler L, Belohradsky BH, Wintergerst U.

Eur J Med Res. 2002 Jul 24;7(7):330-4.

PMID:
12176683
6.

Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study.

Nieuwkerk PT, Sprangers MA, Burger DM, Hoetelmans RM, Hugen PW, Danner SA, van Der Ende ME, Schneider MM, Schrey G, Meenhorst PL, Sprenger HG, Kauffmann RH, Jambroes M, Chesney MA, de Wolf F, Lange JM; ATHENA Project..

Arch Intern Med. 2001 Sep 10;161(16):1962-8.

PMID:
11525698
7.

Gastrostomy tube insertion for improvement of adherence to highly active antiretroviral therapy in pediatric patients with human immunodeficiency virus.

Shingadia D, Viani RM, Yogev R, Binns H, Dankner WM, Spector SA, Chadwick EG.

Pediatrics. 2000 Jun;105(6):E80.

PMID:
10835093
8.

Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088).

Vray M, Meynard JL, Dalban C, Morand-Joubert L, Clavel F, Brun-Vézinet F, Peytavin G, Costagliola D, Girard PM; Narval Trial Group..

Antivir Ther. 2003 Oct;8(5):427-34.

PMID:
14640390
9.
10.

Correlation between self-reported adherence to highly active antiretroviral therapy (HAART) and virologic outcome.

DeMasi RA, Graham NM, Tolson JM, Pham SV, Capuano GA, Fisher RL, Shaefer MS, Pakes GE, Sawyerr GA, Eron JJ Jr.

Adv Ther. 2001 Jul-Aug;18(4):163-73.

PMID:
11697019
11.

Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes.

Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G.

Ann Intern Med. 2007 Apr 17;146(8):564-73.

PMID:
17438315
12.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for Treatment of HIV..

Ann Intern Med. 2002 Sep 3;137(5 Pt 2):381-433.

PMID:
12617573
13.

Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.

[No authors listed]

Prescrire Int. 2004 Aug;13(72):144-50.

PMID:
15532140
14.
15.

Adherence over 48 weeks in an antiretroviral clinical trial: variable within patients, affected by toxicities and independently predictive of virological response.

Nieuwkerk P, Gisolf E, Sprangers M, Danner S; Prometheus Study Group..

Antivir Ther. 2001 Jun;6(2):97-103.

PMID:
11491422
16.

An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children.

Saitoh A, Singh KK, Powell CA, Fenton T, Fletcher CV, Brundage R, Starr S, Spector SA.

AIDS. 2005 Mar 4;19(4):371-80.

PMID:
15750390
17.

Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children.

Resino S, Larrú B, Maria Bellón J, Resino R, de José MI, Navarro M, Léon JA, Ramos JT, Mellado MJ, Muñoz-Fernández MA.

BMC Infect Dis. 2006 Jul 11;6:107.

18.

Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate.

Krogstad P, Wiznia A, Luzuriaga K, Dankner W, Nielsen K, Gersten M, Kerr B, Hendricks A, Boczany B, Rosenberg M, Jung D, Spector SA, Bryson Y.

Clin Infect Dis. 1999 May;28(5):1109-18.

PMID:
10452644
19.

Endocrinologic and immunologic factors associated with recovery of growth in children with human immunodeficiency virus type 1 infection treated with protease inhibitors.

Van Rossum AM, Gaakeer MI, Verweel S, Hartwig NG, Wolfs TF, Geelen SP, Lamberts SW, de Groot R.

Pediatr Infect Dis J. 2003 Jan;22(1):70-6.

PMID:
12544412

Supplemental Content

Support Center